Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis (Q40119794)

17 September 2017

Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis (English)

1 reference

17 September 2017

0 references

1 reference

Ivan Nestorov

1

1 reference

17 September 2017

Alain Munafo

series ordinal

2

1 reference

17 September 2017

Orestis Papasouliotis

series ordinal

3

1 reference

17 September 2017

Jennifer Visich

series ordinal

4

1 reference

17 September 2017

26 February 2008

1 reference

The Journal of Clinical Pharmacology

17 September 2017

1 reference

17 September 2017

48

1 reference

17 September 2017

4

1 reference

17 September 2017

406-417

1 reference

Prospects for B-cell-targeted therapy in autoimmune disease

17 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

An APRIL to remember: novel TNF ligands as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

BLyS and APRIL in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315312

21 January 2018

Identifiers

DOI

10.1177/0091270008315312

1 reference

17 September 2017

1 reference